Section 5: Patient Safety and Quality Assurance

5PSQ-228

PHARMACIST MEDICINES OPTIMISATION AND ERROR MITIGATION AT PAEDIATRIC CRITICAL CARE DISCHARGE: A HUMAN SOLUTION TO AN ELECTRONIC RISK

5PSQ-227

CLINICAL TRIALS: A STANDARDISED SELF-ASSESSMENT TOOL TO REDUCE THE MULTIPLE RISKS OF THE PHARMACEUTICAL CIRCUIT

5PSQ-226

ANALYSIS OF HIGH ALERT MEDICATION PRESCRIPTIONS IN A NURSING HOME

5PSQ-225

ELDER FALLERS: A GROUP AT RISK OF READMISSION?

5PSQ-224

CLINICAL EXPERIENCE OF PEMBROLIZUMAB WITH AXITINIB IN RENAL CELL CARCINOMA

5PSQ-223

DRUGS TO AVOID. AN OPPORTUNITY IN HEALTHCARE PATIENTS: CHECKING PRESCRIRE'S RECOMMENDATIONS

5PSQ-222

ANTICHOLINERGIC RISK IN THE ELDERLY

5PSQ-221

SAFETY PROFILE OF EXPERIMENTAL THERAPIES USED IN THE COVID-19 PANDEMIC BASED ON DATA FROM THE NATIONAL MINIMUM DATA SET

5PSQ-220

DISCREPANCIES BETWEEN PRESCRIPTION AND DISPENSING OF MEDICATION IN AUTOMATIC DISPENSING CABINET

5PSQ-219

THE ROLE OF THE HOSPITAL PHARMACIST IN MONITORING DRUGS AND MEDICATIONS PRESCRIPTION IN THE HOME CARE SERVICE: A GUARANTEE OF APPROPRIATENESS

5PSQ-218

HAEMORRHAGIC TRANSFORMATION AFTER  MECHANICAL THROMBECTOMY ISCHAEMIC STROKE MANAGEMENT: OVERVIEW OF MEDICAL DEVICE VIGILANCE DECLARATIONS

5PSQ-217

MEDICATION RECONCILIATION PROGRAMME OF THE COMPLEX CHRONIC PATIENT IN A TRAUMATOLOGY AND ORTHOPAEDIC SURGERY SERVICE AT HOSPITAL ADMISSION

5PSQ-216

IMPLEMENTATION OF A MEDICATION RECONCILIATION PROGRAMME AS A PATIENT SAFETY STRATEGY

5PSQ-215

CLINICAL RISK MANAGEMENT THROUGH THE “UNIT DOSE” SYSTEM

5PSQ-214

"UNIT DOSE": CLINICAL RISK MANAGEMENT OF COVID-19 PATIENTS TREATED WITH HYDROXYCHLOROQUINE

Pages